The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

E. Nassif, Michael; L. Windsor, Sheryl; A. Borlaug, Barry; W. Kitzman, Dalane; J. Shah, Sanjiv; Tang, Fengming; Khariton, Yevgeniy; O. Malik, Ali; Khumri, Taiyeb; E. Umpierrez, Guillermo; Lamba, Sumant; Sharma, Kavita; S. Khan, Sadiya; Chandra, Lokesh; Gordon, Robert; Ryan, John; Chaudhry, Sunit‐Preet; Joseph, Susan; Chow, C.; Kanwar, Manreet; Pursley, Michael; S. Siraj, Elias; D. Lewis, Gregory; S. Clemson, Barry; Fong, Michael; Kosiborod, Mikhail

doi:10.1038/s41591-021-01536-x

Public

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Published in Nature Medicine • Oct 28, 2021

Authors:

Michael E. Nassif

Sheryl L. Windsor

Barry A. Borlaug

Abstract

Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multice...

Subject

Dapagliflozin

Medicine

Clinical endpoint

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!